6-7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine and Neuroblastoma

6-7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine has been researched along with Neuroblastoma* in 1 studies

Other Studies

1 other study(ies) available for 6-7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine and Neuroblastoma

ArticleYear
Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.
    Cancer cell, 2017, 01-09, Volume: 31, Issue:1

    Given the paucity of druggable mutations in high-risk neuroblastoma (NB), we undertook chromatin-focused small interfering RNA and chemical screens to uncover epigenetic regulators critical for the differentiation block in high-risk NB. High-content Opera imaging identified 53 genes whose loss of expression led to a decrease in NB cell proliferation and 16 also induced differentiation. From these, the secondary chemical screen identified SETD8, the H4

    Topics: Cell Differentiation; Cell Proliferation; Epigenesis, Genetic; Histone-Lysine N-Methyltransferase; Humans; Neuroblastoma; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53

2017